Why Is Adicet Bio (ACET) Stock Down -29.6% Today?
Key Takeaways
- Shares of ACET plunged 29.6% to close at $6.35, down $2.67 from the prior session's close of $9.02.
- The decline came despite the company reporting positive Phase 1 data for its lead lupus therapy, prula-cel — a classic "sell the news" reaction.
- The stock had rallied sharply into the readout, gaining roughly 9% on Friday and trading up 16% in pre-market, setting up heavy profit-taking.
- Analysts responded favorably, with H.C. Wainwright and Wedbush both raising price targets, but that was not enough to offset selling pressure.
- Trading volume surged far above average, signaling intense repositioning around the long-awaited clinical update.
Opening Summary
ACET, the ticker for Adicet Bio, Inc., a clinical-stage biotech developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer, suffered a sharp reversal on Monday. The stock closed at $6.35, a decline of 29.6% from Friday's closing price of $9.02, marking a loss of $2.67 per share. The downward move was driven by a classic "buy the rumor, sell the news" dynamic: investors bid the shares up aggressively ahead of a highly anticipated clinical data update for prula-cel in systemic lupus erythematosus (SLE), only to lock in profits once the results — however encouraging — were finally released.
A Positive Readout Meets Profit-Taking
The catalyst for the day's trading was Adicet's release of updated Phase 1 data for prula-cel, its CD20-targeting allogeneic gamma delta CAR-T therapy, in patients with SLE with or without lupus nephritis (LN). The results were broadly constructive. Among 22 efficacy-evaluable patients, prula-cel demonstrated a 50% complete renal response (CRR) rate at 12 months in lupus nephritis patients and a 54% DORIS remission rate across evaluable patients, all achieved off immunosuppressants. The safety profile also appeared favorable, with no cytokine release syndrome greater than Grade 2 and no reported cases of ICANS or IEC-HS.
Yet despite the encouraging figures, the market reaction was decisively negative. The stock had already run up in anticipation of the update, climbing roughly 39% over the prior six months, gaining 9.07% on Friday, and trading as high as $10.47 in pre-market before the data landed. With elevated expectations already priced in, the release became a trigger for profit-taking rather than further accumulation, and shares reversed sharply from the opening bell.
Analyst Upgrades Couldn't Offset Selling
The day's research commentary painted a notably more bullish picture than the tape suggested. H.C. Wainwright raised its price target on ACET to $34 from $27 while reiterating a Buy rating, and Wedbush lifted its target to $28 from $25 with an Outperform rating, both citing the maturing prula-cel dataset. Analysts highlighted the therapy's potential to deliver durable, immunosuppressant-free remission from a single, off-the-shelf dose, as well as the FDA's alignment on a potential pivotal study in lupus nephritis expected to begin start-up activities in the fourth quarter of 2026. However, positive sell-side revisions were insufficient to stem the tide of selling as shorter-term traders exited positions after the anticipated catalyst materialized.
Market Context and Trading Activity
The magnitude of the move was amplified by exceptionally heavy volume. Turnover ran well above the stock's average daily volume, reflecting aggressive two-way trading as the data readout attracted both dip-buyers and sellers locking in gains. The reversal from the pre-market high underscored the technical damage, with shares slicing through their 50-day moving average near $8.85 and trading toward the lower end of the stock's 52-week range. The move was company-specific rather than a reflection of broad biotech weakness, as the decline stemmed primarily from the unwind of a crowded pre-catalyst position rather than a sector-wide selloff.
What Comes Next for ACET
Looking ahead, investors will focus on Adicet's execution of the pivotal path forward for prula-cel. The company has aligned with the FDA on a single-arm pivotal study in lupus nephritis and plans to initiate start-up activities in the fourth quarter of 2026, with potential expansion discussions to include non-renal SLE patients. Additional data updates are anticipated in the first half of 2027 for systemic sclerosis and around mid-2027 for lupus nephritis and SLE. Key risks include the inherent uncertainty of late-stage clinical development, regulatory decisions, and the company's capital position — Adicet reported $118.2 million in cash and equivalents at the end of the second quarter, expected to fund operations into the second half of 2027. The next earnings report is expected in early November.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated standout performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the strongest performers are featured in this section, helping traders quickly identify tools aligned with today's market environment. Explore the page to see which AI strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ACET turns negative, indicating new downward trend
ACET saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 80 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 60 cases where ACET's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ACET turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
ACET moved above its 50-day moving average on September 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in 235 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ACET may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 137 of 176 cases where ACET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ACET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.703) is normal, around the industry mean (26.453). P/E Ratio (6.061) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributor of pharmaceutical intermediate ingrediants and other industrial chemicals
Industry Biotechnology
Advertisement